Lorella Melillo - Div Ematol & Trapianto Cellule Staminali, Osped Casa Sollievo Sofferenza

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 221 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Matching-adjusted Indirect Comparison of CPX- 351 in Secondary Acute Myeloid Leukemia Between the Registrative Trial and a Real-Life Study

Luana Fianchi,Alfonso Piciocchi,Fabio Guolo,Francesco Marchesi, Giovanni Marsili,Chiara Cattaneo,Michele Gottardi, Francesco Restuccia,Anna Candoni, Elettra Ortu La Barbera, Rita Fazzi,Crescenza Pasciolla, Olimpia Finizio,Nicola Fracchiolla,Mario Delia,Federica Lessi, Michela Dargenio, Valentina Bonuomo,Maria Ilaria Del Principe,Patrizia Zappasodi,Marco Picardi,Claudia Basilico,Monica Piedimonte,Paola Minetto,Patrizia Chiusolo,Lucia Prezioso, Caterina Buquicchio,Lorella Melillo,Daniele Zama,Francesca Farina, Valentina Mancini,Michela Rondoni,Alessandro Busca,Livio Pagano

Annals of Hematologyno. 5 (2025): 2731-2736

Cited0Views0WOSBibtex

REAL-WORLD EFFECTIVENES OF VENETOCLAX COMBINED WITH IPOMETILATING-AGENTS AS A BRIDGE TO ALLOGENEIC TRANSPLANTATION IN ACUTE MIELOID LEUKEMIA: RETROSPECTIVE AND MULTICENTRIC STUDY OF APULIAN HEMATOLOGICAL NETWORK "REP05"

Vincenzo Federico,Rosella Matera,Domenico Pastore,Giuseppe Tarantini,Lorella Melillo,Angelo Michele Carella,Attilio Guarini,Caterina Buquicchio,Lucia Ciuffreda,Mariachiara Abbenante,Paola Carluccio,Crescenza Pasciolla, Mariapaolo Fina,Alessandro Spina, Marina Urbano,Daniela Carlino, Mariangela Lecciso,Michelina Dargenio,Davide Seripa,Pellegrino Musto,Giorgina Specchia,Nicola Di Renzo

BONE MARROW TRANSPLANTATION (2024): 541-542

Cited0Views0Bibtex

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or < 0.1% BCR::ABL1 at 24 Months (major Molecular Response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

BLOOD (2024): 3155-3157

Cited0Views0Bibtex

CML Patients Who Fail to Achieve ≤ 1% BCR::ABL1 at 12 Months or ≤ 0.1% BCR::ABL1 at 24 Months (major Molecular Response, MMR) Show Significantly Inferior Survival, but Not Due to CML-Related Deaths: Data from an Italian Real-Life Observational Study

Bloodno. Supplement 1 (2024): 3155-3155

Cited0Views0Bibtex

IMPACT OF DARA-VTD INDUCTION THERAPY ON HEMATOPOIETIC STEM CELL COLLECTION AND ENGRAFTMENT IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR ASCT: RESULTS OF THE REAL-LIFE PRIMULA STUDY

Vanda Strafella,Immacolata Attolico,Francesco Tarantini,Paola Carluccio,Paola Curci,Nicola Sgherza,Rita Rizzi,Angelo Ostuni,Gabriele Buda,Maria Livia Del Giudice, Viviana Beatrice Valli,Giuseppe Mele, Candida Rosaria Germano,Angela Maria Quinto,Giulia Palazzo,Massimiliano Arangio Febbo,Lorella Melillo,Nicola Di Renzo,Francesco Albano,Pellegrino Musto

BONE MARROW TRANSPLANTATION (2024): 513-514

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn